HPV16 seropositivity relatively common prior to diagnosis of anal cancer
the ONA take:
According to a new study published online in the Journal of Clinical Oncology, researchers from the National Cancer Institute in Bethesda, Maryland, have found that human papillomavirus (HPV) type 16 (HPV16) seropositivity is relatively common in people prior to receiving a diagnosis of anal cancer.
Because the European Prospective Investigation Into Cancer and Nutrition Study found that HPV16 E6 seropositivity was present in people more than 10 years prior to being diagnosed with oropharyngeal cancer, researchers sought to investigate the extent to which HPV16 E6 seropositivity was present before the diagnosis of anogenital cancers.
Researchers identified 400 cases of anogenital cancers and 718 matched control in which prediagnostic blood samples were available. Results showed that 29.2% of those who later developed anal cancer had HPV16 E6 seropositivity compared with 0.6% of controls (OR = 75.9).
HPV16 E6 seropositivity was less common in patients who later developed cervical, penilee, vaginal, and vulvar cancers. HPV16 E6 seropositivity was more common in blood samples drawn closer in time to diagnosis.
HPV16 seropositivity is relatively common in people prior to receiving a diagnosis of anal cancer.
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
- Direct-to-Consumer Genetic Test for Select BRCA Mutations Gets FDA Nod
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|